Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. (Q51251518)

2 April 2018

meta-analysis

0 references

title

Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. (English)

1 reference

2 April 2018

main subject

chronic myeloid leukemia

0 references

1 reference

Zhi-Ping Jiang

1 reference

2 April 2018

Xie-Lan Zhao

1 reference

2 April 2018

Naoto Takahashi

1 reference

2 April 2018

Sabrina Angelini

1 reference

2 April 2018

Biswajit Dubashi

1 reference

2 April 2018

Li Sun

1 reference

2 April 2018

Ping Xu

1 reference

2 April 2018

publication date

19 December 2016

1 reference

2 April 2018

published in

Pharmacogenomics

1 reference

2 April 2018

volume

1 reference

2 April 2018

issue

1 reference

2 April 2018

page(s)

35-56

1 reference

2 April 2018

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Drug transporters and imatinib treatment: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0103

21 January 2018

Identifiers

DOI

10.2217/PGS-2016-0103

1 reference

2 April 2018

1 reference

2 April 2018